#ASCO19: Struggling Nektar braves a tough crowd to offer up 4 new CRs for skin cancer drug
CHICAGO — Nektar Therapeutics $NKTR came back to ASCO looking for some redemption after their pratfall on their NKTR-214 presentation here last year — causing damage to the share price that has yet to be repaired. And while they are a long way from being back in the good graces of the analysts, its top researchers are making a determined march ahead with what they still believe is a game-changing cancer therapy well worth Bristol-Myers’ blockbuster buy-in.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,700+ biopharma pros reading Endpoints daily — and it's free.